BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33124143)

  • 1. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
    Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
    Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
    Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
    Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes.
    Yen FS; Yang YC; Hwu CM; Wei JC; Huang YH; Hou MC; Hsu CC
    Liver Int; 2020 May; 40(5):1089-1097. PubMed ID: 31960563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
    Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
    Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
    Yen FS; Lai JN; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
    BMC Gastroenterol; 2021 Jun; 21(1):263. PubMed ID: 34118892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI; Schafer JA; Heaton AH; Gleason PP
    J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
    Yen FS; Hou MC; Cheng-Chung Wei J; Shih YH; Hsu CY; Hsu CC; Hwu CM
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1255-1264.e18. PubMed ID: 37331413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
    Yen FS; Lai JN; Wei JC; Chiu LT; Hwu CM; Hou MC; Hsu CC
    PLoS One; 2020; 15(12):e0243783. PubMed ID: 33315940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Cardiovasc Diabetol; ; . PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.